Top Markets
Coin of the day
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Hisse Senetlerindeki Sıralama #29609
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Hisse Fiyatı
$0.12715583
Piyasa Değeri
$20.73M
Değişim (1 gün)
2.49%
Değişim (1 yıl)
-36.91%
Ülke
FR
Ticaret GenSight Biologics S.A. (SIGHT)

Kategori

GenSight Biologics S.A. (SIGHT) için EPS
2026 itibariyle EPS TTM: 0
GenSight Biologics S.A. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) 0'dir. 2026 yılı sonunda, şirketin EPS'si 0 idi; bu, 2026 yılındaki EPS olan 0 ile önceki yıla eşit.
GenSight Biologics S.A. için 2026 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
Yıl EPS Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için EPS